Cancer has never been more personal. We all know someone with cancer. They are normal people, living normal lives. They have families, friends, passions and pastimes. Each person living with cancer is unique, and so is their tumour.
The genomic profile, or make-up, of a patient’s tumour may hold the key to treating their cancer. This is where testing can make a difference. The more we know about mutations in cancer-related genes, the better we can diagnose and treat cancer more precisely and personally. As a company dedicated to finding ways to treat the right patient with the right therapy at the right time, Roche has never been more invested in this personalized approach to cancer treatment.
The availability of genomic testing is a potential game changer for many people living with cancer, particularly for specific groups of patients. Patients with certain rare genomic abnormalities, who previously had limited or no available treatment options, are now able to explore a whole new range of possibilities based on one comprehensive test.
“In recent years we have seen significant advances in the type and amount of genomic data that can be obtained from testing a tumour,” says Dr. Jeffrey Rothenstein, Medical Oncologist in the R.S. McLaughlin Durham Regional Cancer Centre at Lakeridge Health “This information can be used to tailor the best treatment for an individual patient, selecting the therapy most likely to work and avoiding treatment that may be ineffective.”
Comprehensive genomic profiling (CGP) is a type of genomic testing. A single CGP test can provide a more complete picture of a cancer tumour by searching for multiple mutations in a large number of cancer-related genes, and matches them with relevant targeted therapies, immunotherapies and clinical trials, to help guide personalized treatment decisions.
Ten or 15 years ago, it would have been very difficult – like finding a needle in a haystack – to give people with tumours harbouring these rare gene fusions a targeted treatment. With advances in the development of targeted treatments and cancer genomic testing, doctors now have more information upon which to make decisions regarding next steps for their patients.
November 30, 2019